BRIEF published on 10/02/2026 at 00:40, 1 month 14 days ago Medicure octroie des options d'achat d'actions à son personnel clé Options D'achat D'actions Medicure Inc. Marché Américain Médicaments Approbation De La TSX
BRIEF published on 10/02/2026 at 00:40, 1 month 14 days ago Medicure Grants Stock Options to Key Personnel Stock Options Pharmaceuticals Medicure Inc. U.S. Market TSX Approval
PRESS RELEASE published on 10/02/2026 at 00:35, 1 month 14 days ago Medicure Announces Grant of Stock Options Medicure Inc. grants stock options to directors, officers, employees, and consultants, aiming at the development and commercialization of pharmaceuticals in the US market Stock Options Pharmaceuticals Medicure Inc. US Market Healthcare Products
BRIEF published on 09/29/2026 at 00:05, 1 month 17 days ago Medicure termine le recrutement pour l'essai clinique de phase 3 MEND-PNPO Essai Clinique Approbation De La FDA MC-1 Médecine Déficit En PNPO
BRIEF published on 09/29/2026 at 00:05, 1 month 17 days ago Medicure Completes Enrollment in MEND-PNPO Phase 3 Clinical Trial FDA Approval Clinical Trial Medicure MC-1 PNPO Deficiency
PRESS RELEASE published on 09/29/2026 at 00:00, 1 month 17 days ago Medicure Announces Completion of Enrollment in Its MEND-PNPO Phase 3 Clinical Trial Medicure completes patient enrollment in MEND-PNPO Phase 3 study evaluating MC-1 for PNPO deficiency. Study progress discussed, including FDA designations and future conference presentations Medicure MC-1 PNPO Deficiency MEND-PNPO FDA Designations
BRIEF published on 09/09/2026 at 00:30, 2 months 7 days ago Medicure dévoile les données de son étude de phase 3 au Congrès européen de l'épilepsie Medicure Inc. Étude MEND-PNPO Déficit En PNPO Essai MC-1 Congrès Sur L'épilepsie
BRIEF published on 09/09/2026 at 00:30, 2 months 7 days ago Medicure Unveils Phase 3 Study Data at European Epilepsy Congress Medicure Inc. PNPO Deficiency MEND-PNPO Study MC-1 Trial Epilepsy Congress
PRESS RELEASE published on 09/09/2026 at 00:25, 2 months 7 days ago Medicure Presents MEND-PNPO Phase 3 Study Design and Baseline Data at the 16th European Epilepsy Congress Medicure Inc. presents design and data from MEND-PNPO Phase 3 study on PNPO deficiency treatment at European Epilepsy Congress. Not FDA-approved yet Clinical Trials Drug Development Medicure Inc. PNPO Deficiency MEND-PNPO
BRIEF published on 08/14/2026 at 23:05, 3 months 1 day ago Medicure annonce ses résultats financiers du deuxième trimestre 2026 et la tenue d'une prochaine conférence téléphonique. Résultats Financiers Medicure Inc. Augmentation Des Revenus ZYPITAMAG® Segment Pharmaceutique
Published on 11/16/2026 at 16:24, 59 minutes ago Avenir Exercises Equity Option to Increase Shareholder Interest of Grid Metals to 19.99%
Published on 11/16/2026 at 15:00, 2 hours 23 minutes ago HM Begins Phase Two Diamond Drilling at the Lewis Pilley's Project
Published on 11/16/2026 at 15:00, 2 hours 23 minutes ago Jaguar Health Reports Third Quarter 2026 Financials
Published on 11/16/2026 at 14:40, 2 hours 43 minutes ago iFabric Corp Announces Record Revenues for Q3 2026 and the Nine Months Ended September 30, 2026
Published on 11/16/2026 at 14:35, 2 hours 48 minutes ago Wi2Wi Reports 35% Revenue Growth to US$2.36M and Returns to Profitability with US$268K Net Income in Q3 2026
Published on 11/16/2026 at 17:00, 22 minutes ago SANY Set to Debut AI Agents and Robotic Machinery at Its Largest-Ever bauma CHINA Showcase
Published on 11/16/2026 at 16:47, 35 minutes ago EQS-Adhoc: Marley Spoon Group SE: Change in the Supervisory Board
Published on 11/16/2026 at 15:00, 2 hours 23 minutes ago MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
Published on 11/16/2026 at 15:00, 2 hours 23 minutes ago INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL D'ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL
Published on 11/16/2026 at 12:13, 5 hours 9 minutes ago Guillemot Corporation S.A. | Weekly report share buyback from November 9 to November 13, 2026
Published on 11/16/2026 at 12:13, 5 hours 9 minutes ago Guillemot Corporation S.A. | Déclaration hebdomadaire des transactions sur actions propres du 9 au 13 novembre 2026